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1. Introduction
Immune treatment for melanoma has roots in clinical observations surrounding regression
of normal nevi, the appearance of halo nevi, the correlation of vitiligo with outcome, the oc‐
currence of spontaneous regression of primary melanomas, nodal metastases of unknown
primary lesions and the occurrence of metastases many years after resection of a primary le‐
sion. Coupling these observations with the observations on the power of the immune system
to reject transplanted organs and control leukemia after allogeneic bone marrow transplant,
the possibility of harnessing and directing this power has been a source of both excitement
and disappointment.
In examining the natural history of normal nevi, it is noted that they undergo a life cycle in
which growth occurs during childhood in the border of the epidermis and dermis (junction‐
al nevi). With increasing age the melanocytes move deeper into the dermis. As adult life
continues they regress in old age. It is not evident that this type of regression has an im‐
mune basis.
Another type of regression called halo nevi is more definitively tied to the immune system
[1]. Akasu, et. al have described halo nevi regression in four stages characterized initially by
pan-T lymphocytes in stage one and the addition of KP-1 positive cells as well as FX IIIa-
positive cells in stage two. Stage three continues with increased numbers of FX IIIa-positive
cells and the addition of Langerhans cells. Finally upon complete regression in stage four
there is a moderate mononuclear infiltrate comprised predominantly of T cells [2]. The role
of natural killer (NK) cells has been studied in normal and malignant melanocytic lesions.
The highest concentration of NK cells was seen in regressing malignant lesions followed by
regressing normal nevi [3]. This type of “spontaneous” regression is observed in other be‐
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nign skin lesions such as keratoachanthomas, and the pathologic studies give insight into
the possibility of stimulating similar immune action against malignancies [1, 2].
The autoimmune condition of vitiligo has been associated with regression of metastases as
well as better outcomes associated with immunotherapy. Vitiligo is mediated through auto‐
antibodies. Antibodies against tyrosinase have been observed in patients with melanoma as
well as vitiligo not associated with melanoma. Other autoimmune effects are well docu‐
mented with immunotherapeutic treatments, indicating the ability of the therapy to break
tolerance to self-antigens [4-7].
Spontaneous regression is observed in primary melanoma [8, 9]. Statistics vary on the inci‐
dence but may be as high as 20%, especially if cases of unknown primary are included.
When remnants of primary lesions are found, they frequently are partially regressed and
show histologic evidence of infiltration by lymphocytes. Although some have observed a
worse clinical outcome with partially regressed primary lesions, patients with nodal meta‐
stases and unknown primaries tend to have a better outcome. The latter observation is at‐
tributed to improved immune surveillance compared to patients with intact primaries
[10-14]. Regression of metastases is less common and has anecdotally been tied to infections
or surgeries. Regression of metastases seems to predict a better overall outcome [15, 16].
The issue of late metastases from primary melanoma is well documented but much harder
to explain. Issues within the tumor microenvironment remain incompletely explored, but
high on the list of explanations is the possibility that the immune system is able to control
proliferation until some as yet undocumented effect allows escape [17, 18].
Early  studies  with  nonspecific  therapies  described  below produced  enough positive  re‐
sults to keep interest in melanoma immunotherapy alive. However, progress in the clinic
has  been  slow  until  very  recently.  Many  issues  have  presented  challenges  to  progress.
Among them is  an  incomplete  understanding of  the  normal  immune system,  including
immune  tolerance  and  the  effects  of  the  tumor  microenvironment  on  the  immune  re‐
sponse.  Drug development required technology to produce biologic agents,  and that ca‐
pability has only recently been perfected. Issues of study design also need to be kept in
mind.  Subject  selection  can  be  difficult  since  these  studies  require  immune competence
but disease advanced enough to answer the question in a reasonable time frame with a
reasonable number of subjects.
2. Biomarkers and endpoints
Biomarkers and surrogate endpoints are tools to obtain information about disease status or
response to interventions. The mainstay of efficacy determination in cancer therapeutic clini‐
cal trials has been the regression of known tumor masses listed as complete response (CR),
partial response (PR), stable disease (SD) or progressive disease (PD) along with various sur‐
vival endpoints: overall survival (OS), disease free survival (DFS) and progression free sur‐
vival (PFS). Each of these endpoints is defined by the study. The response criteria have been
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standardized by various systems. The World Health Organization (WHO) developed the
most commonly used system called response criteria for solid tumors (RECIST) [19]. Recent
developments in assessing response during trials utilizing the drug, ipilimumab, have
served to highlight differences in direct cytotoxic chemotherapy responses and those seen
with immunotherapy. The responses in tumor measurement seen in the ipilimumab trials
did not correspond to the survival endpoints. Subjects had prolonged survival with delayed
or no tumor measurement changes. These observations have led to a new system for assess‐
ing immune based therapies called immune-related response criteria (irRC) [20].
Biomarkers can serve to assess efficacy, but it is difficult to find results that consistently cor‐
relate with clinical response. Some assays can serve as immunologic endpoints in addition
to or instead of tumor regression, PFS and OS in clinical studies. The most frequent meas‐
urements include: antibody titers, delayed type hypersensitivity (DTH) skin tests, enzyme-
linked immunosorbent assay (ELISA), enzyme-linked immunospot assay (ELISPOT),
tetramer markers of antigen specific T cells and other assays indicating that the therapy in‐
duced a response toward its target [21-25].
All of these issues should be considered in assessing the past studies and in the planning
of  future studies.  As we will  discuss,  progress  has been made and enthusiasm is  at  an
all-time high.
2.1. Patient selection
Predicting response to treatment is probably the best way to increase benefit from a variety
of different immunotherapy agents that are currently approved or under investigation for
the treatment of early stage (as adjuvant therapy) or advanced melanoma. Identifying pa‐
tients that are likely to respond to these agents would spare patients unnecessary toxicities
and encourage more research in the field.
Response to treatment may be determined by clinical characteristics or by the presence or
level of biomarkers in the serum or tissue that predict a robust response to immunotherapy
agents. Clinical characteristics such as ulcerated lesions appear to get more benefit from in‐
terferon (IFN) in the adjuvant setting [26]. In addition, Eastern Cooperative Oncology Group
(ECOG) performance status, the number of involved organs and sites of metastases appear
to be treatment factors predicting response to interleukin 2 (IL-2) in some studies [27].
The appearance of serum autoantibodies or clinical manifestations of autoimmunity during
treatment with IFNα-2b was associated with improved outcomes in patients with melanoma
[28]. In addition, multiplexed analysis of serum cytokines appeared to be potentially useful
as a predictive marker of response to IFNα-2b in patients with high-risk operable melanoma
[29]. A serum proteomic analysis has been found to possibly predict response to IL-2 treat‐
ment [30]. In this study, high pretreatment serum vascular endothelial growth factor (VEGF)
and fibronectin levels were predictive of resistance to treatment. A marker of potential inter‐
est in ipilimumab therapy appears to be the absolute lymphocyte count [31]. Absolute lym‐
phocyte counts that exceeded 1 x 109/L at the time of the third ipilimumab dose were
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associated with a survival benefit at one year. Immune responses to NY-ESO-1, a cancer-tes‐
tis antigen, also appear to correlate with clinical benefit from ipilimumab [32].
Gene signatures within the tumor have also shown some correlation with clinical benefit
both for IL-2 and vaccination [33, 34]. Little is known about some of the newer drugs such as
the CTLA-4 antagonists (ipilimumab) or other checkpoint inhibitors. It has been suggested
that the presence of PD-L1 expression detected by immunohistochemistry may predict re‐
sponse to PD-1 antibody therapy [35].
Undoubtedly, utilizing serum and tissue biomarkers for response to treatment is much more
challenging for immunotherapy than in the field of molecular targeted therapies. For exam‐
ple V600E BRAF mutations predict treatment response in patients who receive vemurafenib,
a BRAF inhibitor. In melanoma immunotherapy, however, no serum or tissue biomarkers
have yet been prospectively studied in the context of a clinical trial.
3. Immunoregulatory barriers, immune tolerance and tumor
microenvironment
The immune system is  designed to protect  our bodies from foreign agents.  This protec‐
tion is selective, such that host tissues are recognized as self and preserved (termed im‐
munologic  tolerance),  while  other  agents  are  recognized  as  foreign  and  targeted  for
killing.  Cancer  cells,  however,  present  the  immune  system  with  a  unique  challenge.
While some, such as virally transformed cells, express foreign viral proteins on their sur‐
face, most tumors express normal proteins and carbohydrates. Efforts to understand how
tumors  survive  immunosurveillance  versus  how and when they are  targeted for  killing
have preoccupied scientists  for  well  over  half  a  century.  This  section explores  what  we
currently  know  about  the  complex  interplay  between  the  immune  system  and  cancer
cells as it relates to immunotherapy.
We know now that tumor cells are immunogenic but efficacy is limited due to the lack
of robustness of the response. There are two primary reasons for this:  1) due to the na‐
ture of  the immunogens (self  antigens)  and 2)  the active role-played by tumors to sup‐
press the response.  The mammalian anti-tumor response engages both the humoral and
cell-mediated arms of the immune system through both specific (adaptive) and non-spe‐
cific  (innate)  effectors.  While  cytotoxic  T  lymphocytes  (CTLs),  NK  cells  and  T  helper
(TH) cells are viewed as the most significant players in the anti-tumor response, they are
not alone [36]. Antigen presenting cells (APCs - macrophages and dendritic cells) are ab‐
solutely essential to stimulate a variety of anti-tumor responses across tumor types,  and
anti-tumor antibodies are often easily found in patients with melanoma and many other
solid tumors, indicating a strong humoral response following stimulation by antigen spe‐
cific TH cells [37]. There is accumulating evidence that the CD4+ T cell population is far
more involved in the anti-tumor response than previously thought [38, 39].  When APCs
present antigen to TH cells in the context of a major histocompatibility complex (MHC)
molecule on their  surface,  TH cells  become activated and can stimulate B cells  to result
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in the proliferation of antibody-producing plasma cells and CTLs to result in direct kill‐
ing of the tumor cells. NK cells and macrophages can also directly kill tumor cells alone
or with the help of antibodies or complement.
3.1. Melanoma antigenicity
The goal of cancer immunotherapy is to provoke the immune system to generate a tumor
cell rejection strength response and to prevent recurrence of cancer by establishing long-
term effector cell memory. In order for the immune system to mount an attack against mela‐
noma, it must first recognize the involved tumor cells as foreign or in need of clearing (a
danger signal); it can then target them for killing. Tumor cells, like all cells, display a variety
of proteins on their cell surface, and when antigen is presented in the context of MHC, the
cell may be recognized by the T cell receptor (TCR) on an effector T lymphocyte. Tumor cells
in general and melanoma tissues specifically, are antigenically diverse, and their ability to
survive correlates with the ability of the tumor antigens to avoid detection by the immune
system [40, 41]. Highly antigenic tumor cells are killed off rather quickly, due to the immune
system’s ability to recognize the tumor cells and mount an effective immune response, while
poorly antigenic tumor cells thrive. Tumor specific transplantation antigens (TSTAs) gener‐
ally convey strong immunogenicity. These are antigens expressed on the surface of tumor
cells that are specific to that tumor or type of tumor. However, the majority of antigens asso‐
ciated with melanoma cells are tumor associated transplantation antigens, or TATAs. TA‐
TAs are antigens that are associated with tumor cells, but not unique to tumor cells. TATAs
are far better at preserving a tumor cell under the radar of the immune system, because
these antigens are not danger signals.
Within the tumor microenvironment, tolerance may be naturally overcome by antigen ex‐
pression levels or the timing of antigen expression. Melanomas overexpress many antigens
that are present in normal melanocytes but at lower levels, and expression of these antigens
suggest a progression of differentiation from normal melanocytes to melanomas. For exam‐
ple, a melanoma expressing a mutant triosephosphate isomerase protein was discovered to
bind MHC class II at five times greater affinity than the wild type oligopeptide, resulting in
both a significant increase in surface expression and an increase in immunogenicity [42].
Some melanoma cells overexpress the transferrin receptor by a factor of 100 [43]. Some hu‐
man melanomas overexpress the gangliosides relative to levels seen in normal melanocytes,
illustrating that overexpression of carbohydrates can attract the attention of the immune sys‐
tem, similar to protein antigens [44].
Much of melanoma’s antigenicity comes from the more than 100 identified melanoma TA‐
TAs. Melan-A/MART-1, gp100 and tyrosinase are well studied differentiation antigens ex‐
pressed in both primary and metastatic melanoma [45-53].
Melanoma cells  may also express  oncofetal  antigens which are normally displayed dur‐
ing embryogenesis but only expressed in select tissues, if  at all,  in adults.  These include
the  cancer  germ-line/cancer-testis  (CT)  antigens.  MAGE-A  family  members  and  NY-
ESO-1 are the most significant members of this group to date, and expression of MAGE-
A1  and  MAGE-A4  increases  with  tumor  progression  [47,  54,  55].  NY-ESO-1  is  only
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expressed in adults in testis and placenta tissue, however, it is expressed in up to 40% of
late  stage  melanomas  and  is  highly  immunogenic  [56].  MAGE-6  is  expressed  in  more
than 70% of metastatic melanomas [57].
Identification of melanoma TATAs is crucial as a key strategy for immunotherapy. Adminis‐
tration of vaccines that deliver TATAs can push the immune system into overcoming toler‐
ance. T cells specific for TATAs have been identified in melanoma patients, and
spontaneously occurring circulating T cells reactive to Melan-A and NY-ESO-1 were recent‐
ly found to be predictive of better survival [58]. A recent study reported an analysis of the
human leukocyte antigen 1 (HLA-I) peptidomes from melanomas in four patients, and
while finding that melanoma antigenicity was highly variable, the investigators also found
that the peptidomes were highly immunogenic, identifying new potential peptides for mela‐
noma vaccines [41].
3.2. Immunoevasion strategies
Tumor cells increase their odds of survival by lowering their immunological profiles. TH
cells, CTLs and antibodies specific for TATAs are readily detectable in the blood, lymph no‐
des and tumors of cancer patients. Despite tolerance, the immune system can mount an im‐
mune response to these antigens, but tumors and/or tumor cells may persist, so all the
efforts of the immune system are not enough to clear tumor cells. The immunoevasion strat‐
egies utilized by melanomas are impressive and generally include down-regulation of TA‐
TAs on the tumor cell surface, secretion of immunosuppressive cytokines that affect APCs
and shedding of material that promotes the stimulation of the inhibitory regulatory T cells
(Tregs). Together, these strategies create a toleragenic tumor microenvironment that is both
adaptive to immune pressures and predictive of clinical outcomes.
Many tumor cells stop displaying TATAs or TSTAs on their surface to escape immune rec‐
ognition [59]. Expression of MART-1, gp100 and tyrosinase generally decreases as melano‐
ma progresses [60]. Following immunization with gp100 or MART-1 peptides, melanoma
metastases lost expression of the corresponding TATA, suggesting that TATAs can be
downregulated in direct response to a specific CTL anti-tumor response [45]. This strategy is
specifically adaptive to removing known CTL targets from the tumor population and selects
for proliferation of tumor cells that do not bear antigens yet targeted by the CTL response.
Tumor cells may additionally repress expression of MHC class I proteins by repressing
MHC I gene expression or posttranslational modifications [59]. In fact, many human tumors
demonstrate a decreased expression of MHC I, and the loss of MHC I expression is often
associated with more invasive and metastatic tumors [61, 62]. In melanoma, MHC I expres‐
sion correlates with disease progression, and the lack of HLA I expression and lack of re‐
sponse to T cell based immunotherapy may be linked to acquired β2-microglobulin gene
defects [63-65]. C-myc oncogene overexpression in melanoma also correlates with HLA I
downregulation [66]. The one caveat of this strategy, however, is that a total lack of MHC
expression invites attack by NK cells [67]. To circumvent this, tumor cells often only lower
MHC I expression, retaining some minimal expression to protect themselves while not
alarming the immune system.
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Tumors in general create microenvironments with depressed immune activity such that few
functional cytotoxic cells are found near the developing tumor. One strategy for this in‐
volves the poorly understood regulation of lymphocyte types within the tumor microenvir‐
onment. Moderate to large numbers of tumor infiltrating lymphocytes (TILs) have been
associated with improved survival in melanoma patients; however this has not been ob‐
served consistently [68, 69]. While most patients with melanoma have TILs, the mere pres‐
ence of TILs is obviously not sufficient to mount an effective anti-tumor response [70].
Tumor cells are able to attract a particular type of T cell that is immunosuppressive. Tregs
can directly inhibit and kill CTLs and TH cells, and they functionally drive the tumor’s T
helper Type 2 (Th-2) immune environment by producing the immunosuppressive cytokines
IL-10 and tumor growth factor beta (TGF-β) while suppressing CTL production of immu‐
nostimulatory T helper Type 1 (Th-1) cytokines interferon gamma (IFN γ) and IL-2 [71].
Tregs also negatively regulate effector dendritic cells and NK cells. In melanoma, depletion
of Tregs prior to infusion with activated T lymphocytes (adoptive cell therapy) measurably
improves response rates [72].
Melanoma cells may also create an immunosuppressed microenvironment through galectin
expression [73]. Deregulation of galectins is common in human tumors. Expression of galec‐
tin 3 correlates with melanoma metastasis and poorer disease outcomes, perhaps through
induction of TIL apoptosis. Galectin 1 may also induce apoptosis of T cells and this may be
an important mechanism of tumor evasion for melanoma. Additionally, galectins 1 and 3
convey resistance to apoptosis in tumor cells, though this is less studied in melanoma.
Immunosuppression similar to that found in the tumor microenvironment can also be found
in the sentinel lymph node [71, 74]. Tregs are found in higher numbers in metastatic melano‐
ma sentinel lymph nodes, and as in the tumor microenvironment, this appears to be mediat‐
ed by Th-2 cytokines IL-6, IL-8, IL-10 and TGF-β, among others. This locoregional
immunosupporession is thought to be necessary for metastasis and prepares the lymphatic
environment for the arrival and survival of metastastic cells [75]. While dendritic cells are
detectable in melanoma sentinel lymph nodes, they may be present in lower number and/or
contain a higher percentage of immature dendritic cells that lack the costimulatory mole‐
cules necessary for effective T cell activation [74, 76].
IL-10 and TGF-β are immunosuppressive cytokines utilized by melanoma to create an im‐
munosuppressive microenvironment and progress disease toward metastasis [77, 78]. Both
cytokines can induce T cells to undergo apoptosis; TGF-β can additionally induce apoptosis
in dendritic cells and macrophages. Normal melanocytes are subject to TGF-β anti-prolifera‐
tive regulation, and loss of this phenotype is thought to be a crucial step toward melanoma
development [77]. Neutrophils from patients with melanoma constitutively and spontane‐
ously synthesize IL-10 through activation by serum amyloid A 1 (SAA-1) which is enriched
in melanoma tissue [79].
There are a variety of other general tumor microenvironment conditions and immunoeva‐
sion strategies that melanomas employ to ensure their survival. Hypoxia occurs in solid tu‐
mor masses and is well known to create an immunosuppressive tumor microenvironment
[80]. Tumor cells can also alter the expression of stress proteins that bind NK cells for target‐
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ed killing. Melanoma cells predominantly express the MICA and ULBP2 stress proteins, and
a correlation has been found between poor prognosis and expression of soluble ULBP2 that
is competitive for NK cell binding [81, 82]. Heat shock proteins are well known to promote
tumor growth, invasion and metastasis through a variety of mechanisms [83]. Expression of
heat shock proteins 90 and 40 (hsp90 and hsp40) in melanoma tissue correlates with ad‐
vanced disease and patient survival, in the case of hsp40 [84].
It is important to remember that while immune evasion and creation of an immunsuppres‐
sive tumor microenvironment is highly variable among melanomas, the ability of the tumor
to effectively create a strong toleragenic microenvironment correlates with clinical outcome.
Toleragenic tumor microenvironments are associated with sentinel lymph node involve‐
ment and more advanced disease [74]. Efforts to overcome this tolerance and re-capitulate
the balance of immune system regulators to a state of anti-tumor effectiveness comprise the
field of immunotherapy, and success in this therapeutic approach holds tremendous prom‐
ise for not only halting tumor progression but for turning back the clock to ultimately result
in tumor clearance.
3.3. Immunotherapy strategies
Most immunotherapy efforts strive to activate T cells and specifically CTLs. Therapeutic
melanoma vaccines may enhance antigen presentation directly through peptides or DNA. A
synthetic peptide vaccine targeted to the melanoma gp100 TATA, for example, has resulted
in good objective clinical responses [85]. Vaccines may also rely on the assistance of dendrit‐
ic cells, a key stimulator of immune cells [86-88]. The goal is to utilize TSTA or TATA anti‐
gens to provoke the development and proliferation of cytotoxic cells directed against tumor
cells, thereby overcoming tolerance.
Adoptive cell transfer or therapy (ACT) is a passive immunotherapeutic approach in which
a patient’s antigen-specific cells are expanded and activated ex vivo and then reintroduced
following radiation or chemotherapy [89]. TILs, autologous T cell clones, donor anti-tumor
lymphocytes and genetically engineered lymphocytes have all been used in this strategy.
Some encouraging results have been seen in melanoma patients with advanced disease [90].
In three separate trials, autologous TILs provided through ACT and administered with IL-2
to metastatic melanoma patients resulted in up to a 72% objective response rate, and 22% of
the 93 subjects had complete tumor regression [91]. ACT employing autologous T cells tar‐
geting NY-ESO-1 resulted in objective responses in five of 11 metastatic melanoma patients
and two complete regressions at one-year post-procedure [92]. While it is argued that ACT
is more effective in metastatic melanoma than ipilimumab (see below), it is practically more
complex to administer and less accessible for a majority of patients [90].
Cytokines have shown efficacy in high risk local and metastatic melanoma patients as well.
IL-2 and IFNα-2b have been investigated the most. IL-2 alone produces a durable remission
in some patients, though it is often associated with significant side effects, and better out‐
comes may be obtained by combining it with other therapeutic approaches [93]. A pooled
analysis of nearly 2,000 stage IIB and III melanoma patients indicated that adjuvant high
dose IFNα-2b prolongs relapse free survival in patients [94].
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At present, the greatest promise for metastatic melanoma patients lies in immunomodulato‐
ry antibody therapy against immunological checkpoints. Immunotherapies that employ this
targeting strategy are recent and have yielded some of the most promising clinical responses
in decades. Immunological checkpoints are negative regulators of the immune system. Cyto‐
toxic T lymphocyte antigen 4 (CTLA4) is found on naïve T cells and Tregs; upon activation it
turns off TCR signaling and serves to stop activation of targeted T cells. Antibodies to
CTLA4 prevent this from happening and prolong and intensify T cell activation [36]. Ipili‐
mumab was approved by the U.S. Food and Drug Administration (FDA) in 2012 for the
treatment of metastatic melanoma owing to the overall survival benefit observed in a phase
III study that has now resulted in durable responses lasting 8 years and beyond [95]. Al‐
though ipilimumab is the only FDA-approved checkpoint inhibitor indicated for treatment
of melanoma, there are others in the pipeline [96]. Tremelimumab is another CTLA4 anti‐
body, and there are several programmed death ligand 1 (PD-1) antibodies undergoing clini‐
cal development as well [97, 98]. Though both CTLA4 and PD-1 antibodies have
demonstrated significant improvement in clinical outcome for metastatic melanoma pa‐
tients, they are not effective in all patients and cause a new and unique spectrum of side ef‐
fects termed “immune-related adverse events.”
4. Nonspecific immune therapy and adjuvants
The success of anti-tumor and antiviral vaccines often requires the use of an adjuvant, a sub‐
stance that significantly enhances the immune response to a coadministered antigen. Only a
handful of adjuvants have both sufficient potency and acceptable toxicity for clinical investi‐
gation. The critical roles of vaccine adjuvants lie in their ability to: (1) enable the use of oth‐
erwise impotent antigens; (2) extend the benefits of vaccination to poor responders (e.g.,
older or immune-compromised patients); and (3) effect dose-sparing of rare and expensive
antigens in short supply (e.g., during an epidemic) [99]. Vaccine adjuvants for the most part
can be evaluated as such only when they are associated with a vaccine. Early therapies were
nonspecific and were thought to produce a general immune response. Many current vaccine
trials utilize nonspecific immune stimulants as adjuncts.
4.1. BCG
Adjuvant therapy of melanoma assumes that treatment will be more effective when the tu‐
mor burden is small. Mycobacterium bovis bacillus Calmette-Guérin (BCG) is an old vac‐
cine/adjuvant used in countries where tuberculosis is widespread. First used in humans in
1921, BCG is made from a strain of weakened bovine tuberculosis bacterium. The local and
systemic effect of BCG has been known for decades and is an immunomodulating agent for
melanoma. BCG therapy induces a massive local immune response characterized by the ex‐
pression of multiple cytokines. A significant correlation between a reduced risk of melano‐
ma and BCG and vaccinia vaccination in early childhood or infectious diseases later in life
has already been reported from the FEBrile Infections and Melanoma (FEBIM) multicenter
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case-control study [100]. Such observations suggest that BCG can augment immune respons‐
es and be used in adjuvant therapy strategies.
Phase II trials indicate that active specific immunotherapy can alter the natural course of
American Joint Committee on Cancer [AJCC] Stage III and IV melanoma following surgical
resection of nodal or distant metastases. Initial adjuvant immunotherapy trials demonstrat‐
ed a greater disease-free interval in patients treated with BCG compared with historical con‐
trols [101]. In one study 149 patients at high risk of recurrence after surgical treatment of
local or regional malignant melanoma were given BCG for 2 years and were followed up for
a median of 28 months from the start of immunotherapy [101]. Studies such as these suggest
that improved survival rates following recurrence might be explained by the pattern of re‐
currence; suggesting local or regional sites might be more responsive to treatment. Mecha‐
nistic studies suggest that tumor necrosis factor (TNF)-related apoptosis-inducing ligand
(TRAIL) is induced by BCG treatment. Subsequently, BCG and components of the mycobac‐
terial cell wall can directly stimulate the release of soluble TRAIL through toll-like recep‐
tor-2 (TLR2) recognition that is augmented by IFN. Based on the need for a Th-1 cytokine
response to BCG therapy for therapeutic results, it might be proposed that cells migrating in
response to BCG treatment release TRAIL. In addition, IFN acts to augment and prolong the
amount of TRAIL released by effector cells, resulting in an effective therapeutic outcome.
Early trials of BCG-based immunotherapy for melanoma consistently showed a trend to‐
ward improved clinical  outcomes in patients treated with BCG compared with observa‐
tion alone (reviewed by [102]).  However,  mature results  of  a phase III  randomized trial
of BCG versus observation and BCG plus dacarbazine versus BCG in the adjuvant thera‐
py of AJCC stage I-III melanoma (E1673: an ECOG trial) ascribes no benefit for BCG for
this patient population [103]. As early as 1976 BCG was tested as an immunotherapy sys‐
temic adjunct to surgery in malignant melanoma [104]. In 1984 a polyvalent BCG formu‐
lation  along  with  Canvaxin  began  testing  in  phase  II  trials  as  postsurgical  adjuvant
therapy for stage III melanoma [105], with results from such trials summarized as no ap‐
parent benefit from vaccination [106, 107].
Although experiments with animals have demonstrated that BCG mediates anti-tumor ac‐
tivity, most randomized adjuvant clinical trials have failed to show significant benefit to pa‐
tients with malignant melanoma. This may be because there is no accepted clinical
technique for monitoring in vivo BCG activity. As a result the optimal route of administra‐
tion and dose of BCG have not been truly determined as well as the optimal BCG strain. At‐
tempts to improve the efficacy of BCG therapy have been made. One approach introduced
the gene encoding the 65 kDa hsp of Mycobacterium tuberculosis into a mouse malignant
melanoma cell line (B16) as proof of principle [108].The 65 kDa hsp was expressed after gene
transduction and significantly enhanced the anti-tumor effect of BCG immunotherapy, fur‐
ther indicating that CD4+ T cells play an important role in this anti-tumor effect.
4.2. DETOX
Many adjuvants currently under evaluation for use in cancer vaccines activate relevant
APCs, such as dendritic cells and macrophages, via TLRs and promote effective uptake,
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processing and presentation of antigen to T-cells in draining lymph nodes. The Gram-nega‐
tive bacterial cell constituent lipopolysaccharide (LPS) is known to possess strong immunos‐
timulatory properties and has been evaluated as an adjuvant for promoting immune
responses to minimally immunogenic antigens, including TATAs. The relatively recent dis‐
covery of TLRs and the identification of TLR4, in particular, as the signaling receptor for lip‐
id A have allowed for a better understanding of how this immunostimulant functions with
regard to induction of innate and adaptive immune responses. Local TLR stimulation is an
attractive approach to induce anti-tumor immunity. Tumor cells respond to TLR ligands
with an increase in MHC class I expression and induce IL-6 secretion in vitro. Melanoma
cells are typically characterized as having low expression of MHC I. Consequently TLR li‐
gands interacting with melanoma cells might enhance MHC class I expression, along with
their targeting by melanoma specific CTLs. Although several lipid A species, including LPS
and synthetic analogs, have been developed and tested as monotherapeutics for the treat‐
ment of cancer, monophosphoryl lipid A (MPL), a ligand for TLR4 has been evaluated as a
cancer vaccine adjuvant in published human clinical trials. MPL comprises the lipid A por‐
tion of Salmonella minnesota LPS [109]. LPS and MPL induce similar cytokine profiles, but
MPL is at least 100-fold less toxic.
DETOX, an adjuvant consisting of MPL and purified mycobacterial cell-wall skeleton (CWS)
is another vaccine potentiating agent. MPL (Corixa Corp., Seattle, Washington, USA) adju‐
vant is a chemically modified LPS derivative that displays greatly reduced toxicity while
maintaining most of the immunostimulatory activity of LPS [110] signaling through TLR4 to
stimulate the innate immune system. MPL adjuvant has been used extensively in clinical tri‐
als as a component in prophylactic and therapeutic vaccines targeting infectious disease,
cancer and allergies. MPL has been administered to more than 300,000 human subjects in
studies of next-generation vaccines, emerging as a safe and effective vaccine adjuvant. In
one study DETOX markedly potentiated antibody but had little effect on DTH responses to
melanoma vaccine immunization. It did not appear to improve DFS in comparison to alum
in this non-randomized study [111]. DETOX has been formulated into Melacine (Corixa
Corp.), a vaccine prepared from the lysate of two melanoma cell lines adjuvanted with DE‐
TOX. In clinical trials with Melacine, tumor progression is delayed in the vaccine-treated pa‐
tients, although this was only observed in patients with certain HLA phenotypes.
The potency of local TLR treatment in therapy demonstrates that local treatment with TLR
adjuvants like MPL might effectively restore anti-tumor immunity. Melacine is available for
sale in Canada.
4.3. QS-21
Saponins are natural glycosides of steroid or triterpene which exhibit many different bio‐
logical and pharmacological activities [112]. Notably, saponins can activate the mammali‐
an  immune system,  and this  has  led to  significant  interest  in  their  potential  as  vaccine
adjuvants.  The most widely used saponin-based adjuvants are Quil A and its derivative
QS-21,  isolated from the bark of the Quillaja saponaria Molina (Chilean soap bark tree);
these  have  been  evaluated  in  numerous  clinical  trials  [113].  Their  unique  capacity  to
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stimulate both the Th-1 immune response and the production of CTLs against exogenous
antigens makes them ideal for use in subunit  vaccines and vaccines directed against in‐
tracellular pathogens as well as cancer.
QS-21 possesses an ability to clinically augment significant antibody and T cell responses
to  vaccine  antigens  against  a  variety  of  infectious  diseases,  degenerative  disorders  and
cancers. Currently, there exists no rapid in vitro biological screen for assessing the poten‐
tial  efficacy of  saponin vaccine adjuvants,  given that  the mechanism by which saponins
augment the immune response is unknown. As a result, evaluation of novel saponins as
immunostimulants typically proceed directly to preclinical studies involving mouse vacci‐
nation with antigens [99, 112-114].
QS-21 appears to augment both Th-1 and Th-2 type responses and to favor the in vivo pri‐
ming of antigen-specific CD8+ cytotoxic cells. QS-21 has been used in a variety of melanoma
targeting vaccines [115]. QS-21 has been shown to be superior to some vaccine formulations
such as GM2-KLH plus QS-21 vaccine compared to GM2/BCG vaccine [115]. Efforts to fur‐
ther advance QS-21 in the clinic, as well as to illuminate its unknown mechanism of action,
require access to adjuvant-active samples of known composition [114]. The recent synthesis
of active molecules of QS-21 has provided a robust method to produce this leading vaccine
adjuvant in high purity as well as to produce novel synthetic QS-21 congeners designed to
induce increased immune responsiveness and decreased toxicity [99, 112-114].
4.4. Montanide
Mineral oils are known to be very efficient adjuvants but can sometimes induce local reac‐
tions with reactive antigens. In contrast, non-mineral oils are well tolerated but less effective
with poor immunogens. Mineral oils stay at the injection site and are progressively eliminat‐
ed by competent cells like the macrophages. They can also be partially metabolized into fat‐
ty acids, triglycerides, phospholipids or sterols. Water in oil emulsions represent one of the
new promising generations of adjuvants for immunotherapy [116-118]. In this class both
Montanide ISA 51 and 720 have been tested in animals and thousands of individuals and
found to be safe. Nevertheless, the proper antigen concentration has yet to be established
[116-118]. Adverse effects usually depend on the concentration and nature of the antigen.
The mechanistic premise of emulsions is the “depot” effect, in which the adjuvant protects
the antigen from both dilution and rapid degradation and elimination by the host. By local‐
izing and slowly releasing intact antigen, the adjuvant permits a slow, prolonged exposure
of the immune system cells to a low level of antigen. This prolonged exposure results in con‐
tinued stimulation of antibody producing cells, resulting in the production of high levels of
antibody by the host.
MONTANIDE™ ISA 51 VG has been used in Phase I and II clinical trials for vaccines
against malaria, HIV, and various cancers. MONTANIDE™ ISA 51 VG, has been tested in
AIDS and cancer vaccine trials which together represent more than 10,000 patients and
around 100,000 injections. A survey of ongoing clinical trials listed in ClinicalTrials.gov re‐
vealed 36 trials currently accruing patients that are using the olive-derived Montanide ISA
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51 IFA. The formulation is generally well-tolerated and induces transient local reactions.
Some transient general reactions such as flu-like symptoms are also observed. The results
suggest that numerous repeated vaccine doses can be safely administered. Immunization
with tumor associated antigen peptides in combination with montanide expands tumor an‐
tigen-specific CD8+ T cells in melanoma patients [119-122].
4.5. Cyclophosphamide
High-dose cyclophosphamide (CY) has long been used as an anti-cancer agent, a condition‐
ing regimen for hematopoietic stem cell transplantation and a potent immunosuppressive
agent in autoimmune diseases including aplastic anemia. High-dose CY is highly toxic to
lymphocytes but spares hematopoietic stem cells because of their abundant levels of alde‐
hyde dehydrogenase, the major mechanism of CY inactivation. CY has emerged as a clinical‐
ly feasible agent that can suppress Tregs and allow more effective induction of anti-tumor
immune responses [123]. Tregs have become an important player in regulating anti-cancer
immune responses, with poor prognoses often ascribed to their action [124].
Studies using low dose CY in combination with vaccine components and IL-12 continue to
suggest that CY is a viable addition to affect immune responses [125]. Low-dose CY is found
to selectively deplete CD4+CD25+ T cells (Tregs) and impede tolerance allowing for a more
active immune response. CY preconditioning can enhance the CD8+ T cell response to pep‐
tide vaccination, thus leading to enhanced anti-tumor effects against pre-existing tumors
[126]. CY markedly enhanced the magnitude of secondary but not primary CTL response in‐
duced by vaccines and synergized with vaccine in therapy but not in prophylaxis tumor
models [127].
4.6. Conclusions
The major issues that need to be addressed are designing more effective melanoma vaccines
with a mix of melanoma-associated antigens that can stimulate clinically beneficial anti-tu‐
mor immune responses and finding an adjuvant that can safely, easily and powerfully boost
the frequency and magnitude of these responses.
5. Cytokine therapy
Cytokine therapy has had an important position in the treatment of melanoma in the adju‐
vant and metastatic settings. Various cytokines have been studied with variable success. The
most important cytokines in melanoma treatment thus far have been IFN, IL-2, IL-21 and
GM-CSF.
5.1. IFN
Interferon IFN is a pleotropic cytokine that exerts anti-tumor activity through numerous
mechanisms. High-dose IFNα-2b was approved by the FDA in 1995 for adjuvant therapy of
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resected stage IIB and III melanoma based on the results of ECOG E1684 [128]. This was a
randomized controlled study of IFNα-2b administered at doses of 20 megaunits/m2/d intra‐
venously (IV) 5 days per week for 1 month and 10 megaunits/m2 3 times per week subcuta‐
neously (s.c.) for 48 weeks versus observation in 287 patients. Through this study IFNα-2b
was the first agent to show a significant benefit in relapse-free survival (RFS) and OS of
high-risk melanoma patients in a randomized controlled trial. A subsequent study [129]
(E1690) with a total of 642 patients evaluated the efficacy of high-dose IFNα-2b for 1 year (20
megaunits/m2/d IV 5 days/week for 4 weeks; 10 megaunits/m2 s.c. TIW for 48 weeks) and
low-dose IFNα-2b (3 megaunits/d TIW) for 2 years versus observation in high-risk (stage IIB
and III) melanoma with RFS and OS as end points. The results of the intergroup E1690 trial
demonstrated a RFS benefit of IFNα-2b that was dose-dependent and significant for the
high-dose INFα-2b. Neither high-dose nor low dose IFNα-2b demonstrated an OS benefit
compared with observation at the time.
Pooled data from E1684 and E1690 showed that RFS, but not OS, was significantly pro‐
longed for patients treated with high dose IFN versus observation [94]. Long term OS data
from E1684 also shows a diminishing level of statistical significance (P=.02 at 7 years, but P=.
09 at 12.6 years’ median follow-up) [94]. Additional studies by the Eastern Organisation for
Research and Treatment of Cancer (EORTC) [130] with adjuvant pegylated IFNα-2b (6
µg/kg per week for 8 weeks followed by 3 µg/kg per week for an intended duration of 5
years) showed a similarly significant and sustained effect on RFS.
The effect of IFNα on OS has been criticized strongly since only two studies (E1684 and
E1694) have shown a survival benefit. In contrast, several other studies mentioned above
have shown RFS as the only benefit. A recent meta-analysis [131] showed statistically signif‐
icant improvement in both RFS and OS. The meta-analysis included 14 randomized control‐
led trials published between 1990 and 2008 and involved 8,122 patients, of which 4,362 were
allocated to the IFNα arm. Subgroup analysis and meta-regression did not identify an opti‐
mal IFNα dose, the optimal treatment duration or a subset of patients more responsive than
others to the adjuvant therapy. Therefore, the role of IFN in the adjuvant setting remains
controversial by many. The National Comprehensive Cancer Network (NCCN) has a 2B rec‐
ommendation for the use of IFN as an adjuvant treatment, and enrollment in clinical trials is
encouraged.
Single-agent IFN has demonstrated modest activity in patients with metastatic malignant
melanoma with response rates between 10%-20% [132]. Most of the responses were transient
and usually restricted to cutaneous metastases [133]. Therefore, its use in the metastatic set‐
ting has been employed more frequently in combination with chemotherapy (biochemother‐
apy) with improved response rates but without a well documented survival benefit [134].
Other cytokines have been subsequently evaluated, and the interest in IFN has been shifted
to the adjuvant setting as mentioned above.
5.2. IL-2
One of the most promising immune stimulating cytokines has been interleukin 2 (IL-2).
High dose IL-2 produces not only PRs but also CRs. Overall objective response rates (ORR)
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are approximately 16% with IL-2 with a 6% CR rate [93]. Importantly, some patients ach‐
ieved durable CRs which led to the approval of high-dose IL-2 for patients with metastatic
melanoma. Responses occurred with all sites of disease and in patients with large tumor
burdens (unlike previously with IFN). Disease progression was not observed in any patient
responding for longer than 30 months, and in some cases where disease progression was ob‐
served, durable disease free status was achieved with metastasectomy.
The use of high-dose IL-2, however, is limited by its severe toxicity; 2.2% of the patients in
the National Cancer Institute (NCI) trial series died from treatment-related toxicities with
bacterial sepsis being the predominant cause of death. No deaths were observed in the NCI
series when antibiotic prophylaxis was implemented. However, the incidence of grade 3-4
toxicities remains high, ranging between 1-64%. Alternate regimens have been employed in‐
cluding low dose IL-2 alone or in combination with IFN-α or chemotherapy. However, there
is evidence that suggests that high dose IL-2 is a more efficacious regimen. A phase II study
showed durable CRs with high-dose bolus IL-2 in patients with metastatic melanoma who
have experienced progression after biochemotherapy [135]. In addition, IL-2 based bioche‐
motherapy regimens have not shown significantly better results than chemotherapy alone,
presumptively due to the fact that high dose IL-2 is not utilized [136].
5.3. IL-21
The  role  of  other  cytokines  has  also  been  explored.  IL-21  has  recently  emerged  as  a
promising cytokine [137].  In  an open-label,  multicenter  phase  II  study,  IL-21  was given
as a bolus injection on days 1 through 5 on alternate weeks using three different dosing
regimens in 40 patients  with malignant melanoma. Cohort  1  received 50 µg/kg per day
by outpatient IV bolus injection for 5 days of each week during weeks 1, 3, and 5 of an
8-week cycle. Cohort 2 received 30 µg/kg per day on the same schedule, and cohort 3 re‐
ceived 50 µg/kg per day for 5 days of each week during weeks 1 and 3 of a 6-week cy‐
cle. The primary objective of the study was to assess efficacy (ORR and PFS) of IL-21 in
this population. The ORR to IL-21 was 22.5%. The median PFS was 4.3 months and the
median OS was 12.4 months, suggesting that this is an active agent that warrants further
investigation.  The 30  µg/kg per  day dose  and schedule  was  generally  well  tolerated as
an outpatient  regimen,  with  the  most  common adverse  events  being  flu-like  symptoms
and rash, most of which were grade 1 or 2.
5.4. GM-CSF
Granulocyte macrophage-colony stimulating factor (GM-CSF) has also been studied mostly
in the adjuvant setting. Forty-eight patients with stage III or IV melanoma were treated in a
phase II trial with long-term, chronic, intermittent GM-CSF after complete surgical resection
of disease [138]. The median survival duration was 37.5 months in the study patients versus
12.2 months in the matched controls. OS and DFS were significantly prolonged in patients
who received GM-CSF compared with matched historical controls, and treatment was well
tolerated with acceptable toxicity. A phase III prospective, randomized, placebo-controlled
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study (E4697) failed to show an OS benefit but improved DFS in patients with completely
resected high-risk melanoma with minimal toxicity [139].
5.5. Conclusions
Immune stimulating cytokines have historically been an important part of the therapeutic
armamentarium for early stage and metastatic melanoma due to the importance of the im‐
mune system in this disease. The currently approved IFN and IL-2 treatments in the adju‐
vant and metastatic settings, respectively, provide modest but reproducible clinical benefits.
Their use is limited by toxicity and the lack of clearly defined predictive-to-treatment tools.
In the near future, the development of novel molecular and immune treatments might limit
their role. However, the durable responses that we see in some patients should not be ignor‐
ed, and the search for predictive biomarkers should continue.
6. Vaccine therapy
The purpose of cancer vaccines is to evoke an immune response against malignant cells. One
of the earliest approaches was taken more than 100 years ago when Dr. William Coley treat‐
ed patients with Coley’s Toxin derived from bacteria [22]. Although clinical success in indi‐
vidual trials has been uncommon, a meta-analysis of 56 clinical trials showed that evidence
of an immune response predicted a better outcome [140]. Vaccines are of various types, each
with advantages and disadvantages. The following discussion will be divided by the vac‐
cine type, and when available, clinical data in advanced and adjuvant settings.
6.1. Autologous whole cell vaccines
Vaccines derived from the patient’s own cancer should have the advantage of presenting the
complete array of tumor antigens, both internal and external. There should be less chance of
the remaining tumor mutating sufficiently to avoid detection. These vaccines should be able
to produce both humoral and cellular immunity [141]. Autologous vaccines are produced by
irradiating resected tumors or by establishing cell lines from resected specimens [22]. This
approach is difficult from a technical and regulatory standpoint. It is further hampered by
limiting eligible patients to those with accessible cancer and those who can wait for the vac‐
cine development [141]. These vaccines have used the cells themselves with adjuvants or
cells modified to produce cytokines.
An autologous whole cell vaccine is exemplified in work done by Berd, et. al. Early reports
demonstrated clinical response to an irradiated autologous tumor cell vaccine given with
BCG as an adjuvant. Subsequently, low dose CY preceded vaccination. In that study there
were 5 responses in the 40 subjects assessable for response. The responses were associated
with DTH responses [142]. In the next series of studies the vaccine was modified by the
hapten, dinitrophenyl (DNP), and BCG and CY were maintained. Sixty two subjects with re‐
sected nodal metastases were vaccinated and compared to historical controls. There was a
perceived benefit in disease progression and survival, especially in subjects over the age of
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50 years [143]. In an expansion of this initial trial to 214 subjects, there was an improvement
in OS in patients who developed a positive DTH response (59.3% vs 29.3%; p < 0.001). Forty-
seven percent of subjects had a DTH response [144].
Work done by the National Biotherapy Study Group utilizing patient specific autologous tu‐
mor cell lines in patients with melanoma has been summarized [145]. This series of studies
utilized different adjuvants including BCG, IFNγ and GM-CSF. Once again, benefit was
seen in groups developing a positive DTH response [145-147]. Additional non-randomized
studies show positive outcomes as well, but without randomization, the results are difficult
to weigh [148-151]. Some studies have genetically modified the tumor cells to secret cyto‐
kines. These trials have also been non-randomized but have shown positive results [152,
153]. A randomized trial using an autologous tumor vaccine processed to extract hsps com‐
pared to physician’s choice was conducted in 322 patients with metastatic disease. There
was no difference between the two groups overall, but subjects with M1a disease had longer
survival when treated with vaccine [154].
6.2. Allogeneic whole cell vaccines
Allogeneic whole cell vaccines are produced by a cell line or cell lines. Other features are
similar to the autologous cell vaccines. The advantage of this approach is that it is more
readily available and would prevent delays in treatment that are necessitated by the autolo‐
gous vaccines. However the antigens may not match those of the patient’s melanoma [141].
A vaccine developed by Dr. Donald Morton beginning in 1984 from three irradiated melano‐
ma cell lines has been studied the most extensively. It is named Canvaxin (CancerVax Corp.,
Carlsbad, California, USA). There were extensive phase II trials done in patients with stage
IV disease demonstrating response to therapy. However, when tested in randomized multi-
center trials in resected stage III and IV melanoma patients, there was no benefit noted.
However, the trials were stopped prior to their planned accrual by the data safety monitor‐
ing board for futility [141, 155-157]. Other allogeneic vaccines including VACCIMEL (pro‐
duced from three melanoma cell lines) have had less mature study and similar biomarker
results [158].
6.3. Tumor lysate vaccines
Tumor lysate vaccines have similar advantages and disadvantages of allogeneic vaccines.
The vaccinia  melanoma oncolysate  (VMO) vaccine is  prepared from four allogeneic  cell
lines  infected  with  the  vaccinia  virus  to  increase  immunogenicity.  The  cells  are  then
lysed by  sonication  prior  to  administration.  VMO yielded encouraging phase  II  results,
however,  there was no statistically significant increase in DFS when studied in an adju‐
vant setting [157, 159].
A second tumor lysate vaccine, called Melacine (Corixa Corp., Seattle Washington, USA)
is  also  a  cell  lysate  vaccine  which has  been tested in  two large  randomized trials.  One
adjuvant trial conducted by the Southwest Oncology Group (SWOG) studied 600 eligible
patients treated with Melacine along with the adjuvant DETOX versus observation. To be
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eligible the subjects had to have intermediate thickness lesions and negative nodes; how‐
ever, sentinel lymph node biopsy was not required, and therefore, the staging in this tri‐
al would be considered inadequate by today’s standards. Survival in the overall analysis
showed  no  difference  between  treatment  and  observation,  however,  a  subgroup  of  pa‐
tients expressing certain MHC classes showed a five-year survival rate of 83% compared
to  59%  in  the  observation  group.  This  subset  analysis  was  statistically  significant
[160-163].  An Ad Hoc Melanoma Working Group reported a separate study in stage III
resected patients comparing high dose IFN for one year versus low lose IFN plus Mela‐
cine with DETOX for 2 years. Six hundred subjects were registered. There was no differ‐
ence in outcome [164]. As described above, high dose IFN had been shown previously to
be superior to observation.
6.4. Protein vaccines
Protein vaccines using purified proteins have the potential for a broader spectrum of anti‐
gens, but they can be more complex to manufacture and monitor for response [157]. The use
of hsps, which have a normal function in chaperoning proteins as they are processed into
peptides, has also been explored with peptide vaccines [154] and may have a role in identi‐
fying new antigenic targets [165]. A trial using NY-ESO was found to produce a strong im‐
munologic response after vaccination. There were better clinical outcomes compared to
placebo in those given the protein vaccine compared to placebo. The adjuvant used in the
trial was ISCOMATRIX [166].
6.5. Ganglioside antigen vaccines
Gangliosides are non-protein antigens (glycosphingolipids containing sialic acids) that have
been shown to elicit antibodies. They are present on melanoma cells (GM2, GD2, GD3) [157,
167]. The GM2 antigen plus BCG versus BCG alone was studied in stage III resected pa‐
tients. There was no difference in DFS, but subjects with IgM antibodies against the antigen
had better outcome [167]. GM2 conjugated to a keyhole limpet hemocyanin (KLH) and ad‐
ministered with the adjuvant QS-21 had better immunogenicity [168]. This same vaccine
was compared to high dose IFN in an Intergroup adjuvant trial in patients with resected
stage IIB or III melanoma. The trial ended when an interim analysis showed therapeutic in‐
feriority in the vaccine arm [169].
6.6. Peptide vaccines
Peptide vaccines have the advantage of being easy to manufacture and have an excellent
safety  record.  However,  there  are  challenges  that  impact  their  effectiveness.  These  in‐
clude the identification of epitopes that stimulate a T cell response, selecting an appropri‐
ate adjuvant,  breaking tolerance without causing limiting autoimmunity,  handling MHC
restriction and assessing the need for multi-epitope vaccines [170]. Peptide vaccines have
been  reported  to  increase  survival  following  resection  of  metastatic  lesions  [171]  and
have been shown to  have increased immune efficacy with various adjuvants  [172,  173].
Use of multiple peptides has been another strategy [121, 174, 175]. An ECOG study test‐
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ing  a  multi-epitope  vaccine  with  GM-CSF and/or  IFNα-2b  showed that  an  immune re‐
sponse  to  the  vaccine  correlated  with  outcome  but  that  the  cytokines  did  not  affect
outcome [176].
One of the most studied peptide vaccines is a modified gp100 peptide antigen. This vac‐
cine has been studied in locally advanced stage III or stage IV patients comparing IL-2 to
IL-2 plus vaccine. The results showed a statistically significant improvement in response
rate and PFS in the vaccine arm [177].  This is in contrast to a report from the Cytokine
Working  Group  analysis  of  three  phase  II  trials  looking  at  a  similar  vaccine  with  IL-2
showing no benefit to the addition of the vaccine [178]. Another phase III study compar‐
ing  ipilimumab  plus  gp100  vaccine  versus  gp100  plus  placebo  versus  ipilimumab  plus
placebo  failed  to  show  a  benefit  to  the  addition  of  the  vaccine,  and  the  vaccine  alone
was inferior [95].
6.7. Monoclonal antibodies
Anti-idiotype vaccines consist of monoclonal antibodies that mimic an antigen. The theoreti‐
cal hypothesis is sound [179-181], but trials have been limited [182-184]. These vaccines have
not been tested prospectively.
6.8. Viral vaccines
Viral vectors can boost the immunogenicity of the vaccines they carry [141, 185]. However
the presence of neutralizing antibodies in the host could play a role [186]. Novel methods of
utilizing this mode of immune stimulation are still being explored [187, 188]. A randomized
trial in stage III resected patients utilizing a vaccinia viral lysate vaccine failed to show bene‐
fit [189]. Transduction of cell lines to produce expression of B7-1and IL-2 have been accom‐
plished and show promising immunostimulatory effects [190, 191]. These techniques are
difficult to pursue from a technical and regulatory standpoint. Recombinant viral vaccines
have also been used to prime dendritic cells [192].
6.9. DNA vaccines
DNA vaccines have the advantage of specificity for the target for which they encode, which
can simplify monitoring, but in general they have not done well in breaking tolerance [141,
193-195]. Two groups have reported on vaccines that rely on production of GM-CSF. Dran‐
off has reported on a vaccine utilizing melanoma cell lines engineered to produce GM-CSF
and has noted improved anti-tumor effects [196]. A different approach using an intralesional
vaccination with an oncolytic herpesvirus encoding GM-CSF has been developed and has
had initial positive results [197, 198]. Another agent called Allovectin-7 consists of a plasmid
containing DNA encoding for the MHC class I gene, HLA-B7. It was administered by intra‐
lesional injection. Early studies showed evidence of biologic activity [199]. Subsequent phase
II studies showed efficacy locally as well as systemically [200-203]. A phase III study has not
yet been reported.
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7. Cellular therapy
The transfer of immunologically competent white blood cells or their precursors into the
host (cellular adoptive immunotherapy, adoptive cell treatment, adoptive cell therapy
[ACT]) has been studied extensively in patients with melanoma over the last 30 years. Since
it was thought that the effect of IL-2 is potentiated by this form of therapy, various studies
examined the role of combination regimens with lymphokine-activated killer cells (LAK
cells) or TILs with or without lymphodepletion with mixed results.
7.1. TILs
Earlier studies with LAK cells [204] showed promise, improving the responses with IL-2. A
randomized study [205] with IL-2 and LAK cells compared to IL-2 alone failed to show sig‐
nificant improvement in survival which tempered the initial enthusiasm. Subsequent stud‐
ies with Tumor Infiltrating Lymphocytes (TILs) [206] showed some response to treatment
(overall ORR in these patients was 34%) when combined with IL-2. Interestingly, there was
no significant difference in the ORR in patients whose therapy with high-dose IL-2 had
failed (32%) compared with patients not previously treated with IL-2 (34%). However, the
responses appeared to be short-lived, probably due to the transient persistence of the trans‐
ferred TILs [207].
The addition of lymphodepletion has been thought to promote the persistence of the trans‐
ferred TILs by eliminating the regulatory cells. Pooled data from three clinical trials employ‐
ing three different lymphodepleting regimens [91] showed high responses between 49-72%.
Ninety-five percent of these patients had progressive disease following a prior systemic
treatment. Twenty of the 93 patients (22%) achieved complete tumor regression, and 19 have
ongoing complete regressions beyond 3 years. The actuarial 3- and 5-year survival rates for
the entire group were 36% and 29%, respectively, but for the 20 complete responders were
100% and 93%. Factors associated with objective response included longer telomeres of the
infused cells, the number of CD8+ CD27+ cells infused and the persistence of the infused
cells in the circulation at one month. This treatment appears to also be helpful in the treat‐
ment of intracranial disease [208].
At this point, there is reserved enthusiasm about the role of TILs with lymphodepletion reg‐
imens. There are several programs within the United States [209] outside of the NCI, where
this work was pioneered, and internationally more groups are starting to employ similar
strategies.
7.2. Dendritic cells
Another form of ACT is the infusion of dendritic cells. There is a lot of interest in devel‐
oping dendritic  cell  based immunotherapy strategies  since the approval  of  sipuleucel-T,
an  autologous  dendritic  cell  based  immunotherapy in  hormone  refractory  prostate  can‐
cer. Dendritic cells are believed to induce a Th-1 response which activates CTLs through
processing  and  presenting  of  peptides  derived  from  the  tumor  protein  antigens.  In  a
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study that evaluated the role of dendritic cells pulsed with Mage-3A1 tumor peptide and
a  recall  antigen,  tetanus  toxoid  or  tuberculin,  6  of  11  patients  with  advanced  stage  IV
melanoma experienced significant regression of their metastases [210]. Resolution of skin
metastases  in two of  the patients  was accompanied by CD8+  T  cell  infiltration,  whereas
nonregressing lesions lacked CD8+ T cells.
In another trial [211] 16 patients with metastatic stage IV melanoma were treated with den‐
dritic cells derived from incubation of peripheral blood mononuclear cells with IL-4 and
GM-CSF and overnight pulsing with several peptides (tyrosinase, gp100 and MART-1). One
patient had a complete remission of lung and pleural disease after two cycles of therapy.
Two additional patients had SD, and two patients had mixed responses. In general, review‐
ing over 30 studies that employed dendritic cell-based treatments [212], it appears that clini‐
cal response (defined as CR, PR or SD) was significantly correlated with the use of peptide
antigens, use of helper antigen or adjuvant and induction of tumor antigen specific T cells.
Although there appears to be a real effect of these treatments on tumor response in a subset
of the treated patients, undoubtedly the success has not been universal and convincing
[213]. This could be due to Tregs that counteract the effect of dendritic cells. In addition,
melanoma can also mediate dendritic cell suppression possibly through the activation of the
MEK1/2-p44/42 axis [214]. Finally, little is known about optimal dendritic cell generation,
administration and immune monitoring which could hamper progress in this field.
8. Enhancement of cellular immunity
8.1. Checkpoint inhibitors
Monoclonal antibodies targeted against a number of regulatory immune system checkpoints
are being evaluated in patients with advanced melanoma. The recently approved ipilimu‐
mab remains the prototype, but others are currently being evaluated in several trials.
8.2. Ipilimumab
Ipilimumab is a monoclonal antibody against cytotoxic T-lymphocyte antigen 4 (CTLA-4).
In two phase III trials ipilimumab showed improved OS in patients with advanced melano‐
ma. In the first one [95], 676 HLA-A*0201–positive patients with unresectable stage III or IV
melanoma, whose disease had progressed while they were receiving therapy for metastatic
disease were studied. More than 70% of the patients had M1c disease (presence of visceral
metastases), and more than 36% had elevated lactate dehydrogenase levels. The patients
were randomly assigned, in a 3:1:1 ratio, to receive ipilimumab plus gp100, ipilimumab
alone or gp100 alone. Ipilimumab, at a dose of 3 mg/kg of body weight, was administered
with or without gp100 every three weeks for up to four treatments. HLA-A*0201–positivity
was required because of the use of the gp100 vaccine. Certain patients were allowed to have
another course of treatment upon progression. The primary end point was OS.
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The median OS was 10.0 months among patients receiving ipilimumab plus gp100, as com‐
pared with 6.4 months among patients receiving gp100 alone (hazard ratio for death, 0.68;
P<0.001). The median OS with ipilimumab alone was 10.1 months (hazard ratio for death in
comparison with gp100 alone, 0.66; P=0.003). No difference in OS was detected between the
ipilimumab groups (hazard ratio with ipilimumab plus gp100, 1.04; P=0.76). The best OR or
SD was seen in the ipilimumab-alone group (10.9%) and a disease control rate (the propor‐
tion of patients with a PR, CR or SD) of 28.5%. In the ipilimumab-alone group, 60.0% main‐
tained an OR for at least two years. Responses to ipilimumab continued to improve beyond
week 24: in the ipilimumab-alone group, two patients with SD improved to a PR, and three
with a PR improved to a CR. Interestingly, among 31 patients given reinduction therapy
with ipilimumab, a PR, CR or SD was achieved by 21 weeks. Grade 3 or 4 immune-related
adverse events occurred in 10 to 15% of patients treated with ipilimumab and in 3% treated
with gp100 alone. There were 14 deaths related to the study drugs (2.1%), and seven were
associated with immune-related adverse events.
In the second phase III study [215], 502 patients with previously untreated metastatic mela‐
noma were assigned in a 1:1 ratio to receive 10 mg/kg ipilimumab plus 850 mg/m2 dacarba‐
zine or 850 mg/m2 dacarbazine plus placebo, given at weeks 1, 4, 7 and 10, followed by 850
mg/m2 dacarbazine alone every three weeks through week 22. Patients with SD or an OR
and no dose-limiting toxic effects received ipilimumab or placebo every 12 weeks thereafter
as maintenance therapy. Similarly with the previous study a significant number of patients
had poor prognosis based on the presence of visceral metastases and increased lactate dehy‐
drogenase. The primary end point was OS.
OS was significantly longer in the group receiving ipilimumab plus dacarbazine than in the
group receiving dacarbazine plus placebo (11.2 months vs. 9.1 months), with higher survival
rates in the ipilimumab–dacarbazine group at one year (47.3% vs. 36.3%), two years (28.5%
vs. 17.9%), and three years (20.8% vs. 12.2%) (hazard ratio for death, 0.72; P<0.001). The rate
of disease control (PR, CR or SD) did not differ significantly between the two groups: 33.2%
in the ipilimumab–dacarbazine group and 30.2% in the dacarbazine group (P=0.41). The rate
of best OR (PR or CR) was 15.2% in the ipilimumab–dacarbazine group and 10.3% in the da‐
carbazine group (P=0.09). However, the median duration of response among all patients
with a PR or CR was 19.3 months (95% CI, 12.1 to 26.1) in the ipilimumab–dacarbazine
group and 8.1 months (95% CI, 5.19 to 19.8) in the dacarbazine group (P=0.03). In addition,
some patients in the study who were receiving ipilimumab had an improvement from PR to
CR after six months. Grade 3 or 4 adverse events occurred in 56.3% of patients treated with
ipilimumab plus dacarbazine, as compared with 27.5% treated with dacarbazine and place‐
bo (P<0.001). No drug-related deaths or gastrointestinal perforations occurred in the ipili‐
mumab–dacarbazine group.
Patients with untreated brain metastases were excluded from both phase III studies. Howev‐
er, phase II data indicate that ipilimumab has activity in patients with brain metastases
[216]. The currently approved dose is 3 mg/kg based on the registration trial [95], however
other doses and schedules [217] have been used that do not appear to produce significantly
different results but appear to increase toxicity.
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The experience with ipilimumab has shown that a subgroup of patients may experience a
late response and more interestingly, some patients exhibit apparent disease progression af‐
ter 12 weeks of ipilimumab followed by subsequent disease regression [218]. Therefore, tra‐
ditional criteria (e.g. RECIST) may not apply in the evaluation of patients who receive
ipilimumab or similar treatments, and different criteria may need to be established in the in‐
terpretation of efficacy data in clinical trials [20].
Based on the favorable results from the ipilimumab studies, other anti-CTLA4 antibodies are
currently being evaluated such as tremelimumab. Tremelimumab has a longer half-life than
ipilimumab and is dosed less frequently. Phase II data showed results similar to ipilimumab
with durable responses suggesting a potential role for tremelimumab in melanoma [219].
However, a phase III trial comparing tremelimumab and chemotherapy failed to demon‐
strate an improvement in OS [220].
8.3. Toxicity with ipilimumab
The toxicity of ipilimumab appears to be related to the increased activation of the immune
system. A variety of immune mediated adverse events have been observed. Some of them
are life-threatening and the most common are enterocolitis, hepatitis, dermatitis and endo‐
crinopathies, but others such as neurologic complications, ocular symptoms, hematologic
manifestations, vasculitis, et al are also observed.The prompt administration of corticoste‐
roids is paramount when these are observed, and in some cases treatment interruption or
permanent discontinuation is required. A relationship between the development of side ef‐
fects and anti-tumor activity has been proposed by several investigators [218].
8.4. PD-1
Another regulatory checkpoint is Programmed Death-1 receptor (PD-1). Its inhibition is cur‐
rently being evaluated in clinical trials. The PD-1 and PD ligand-1 (PD-L1) interaction is be‐
lieved to affect T cell anti-tumor immunity. Many tumors express high levels of PD-L1.
When PD-L1 interacts with the PD-1 receptor on T cells, T cell function is impaired through
a variety of mechanisms including induction of apoptosis, suppression of proliferation and
inhibition of T cell cytokine production [96]. There are several ways to target PD-1; one way
is targeting the PD-1 receptor and another is targeting the PD-1 ligand. There are several
molecules currently under investigation that target the PD-1 receptor directly (BMS-936558,
CT-011, MK-3475). In a recent study [98], BMS-936558 showed significant anti-tumor activity
in a variety of solid tumors. In melanoma patients response rates were 28% and appeared to
be durable. Interestingly, of 17 patients with PD-L1–negative tumors, none had an OR while
9 of 25 patients (36%) with PD-L1–positive tumors had an OR (P=0.006). CT-011 has demon‐
strated favorable results in hematologic malignancies but has not been well studied in mela‐
noma patients yet [221], although there is an ongoing phase I study being conducted at
present. The role of MK-3475 in melanoma is also currently being evaluated in a phase I tri‐
al. Another molecule which is not probably directly targeting the PD-1 is AMP-224; it is a
fusion protein of B7-DC and an antibody Fc portion. It is not a monoclonal antibody like the
three checkpoint agents mentioned previously, and no data has been reported yet regarding
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its efficacy in human trials. PD-L1 monoclonal antibodies have emerged as another strategy
to affect the PD-1/PD L-1 pathway. A multi-center phase I study evaluating the role of
BMS-936559 in patients with advanced cancers including melanoma showed a 17% response
rate in melanoma patients with some of those being durable responses [97].
8.5. Co-stimulatory agonists
4-1BB or CD137 is a member of the TNF receptor (TNFR) family and provides a costimulato‐
ry signal important to the effective generation of many types of T cell responses. A complet‐
ed phase I study in melanoma with BMS-663513, a fully human anti-CD137 agonist
monoclonal antibody, showed that this agent was well tolerated and three PRs were seen
[222].
OX-40 is another member of the TNFR family. An agonist molecule is also under investiga‐
tion, but mature data are not yet available [223].
8.6. Conclusions
Checkpoint inhibitors and co-stimulatory agonists are improving anti-tumor cellular im‐
munity. In a similar way to the more non-specific activation through cytokines, responses
are durable but are not seen in all patients. This brings up issues such as appropriate patient
selection, biomarker development and optimization of the dose, frequency and administra‐
tion in order to optimize efficacy.
9. Combination approaches
Combination approaches have been traditionally used in the treatment of melanoma (for ex‐
ample different cytokines together or cytokines with chemotherapy). It is quite interesting
that the results of this strategy have not been yet as successful as expected. While new
agents are developed and we understand more about their function, these strategies may be‐
come more successful. At this point there is a lot of interest combining checkpoint inhibitors
with other checkpoint blocking agents, co-stimulatory agonists, chemotherapy, targeted
agents (such as B-type Raf kinas [BRAF] inhibitors) and radiotherapy. Interestingly, the
BRAF inhibitors appear to improve T cell recognition of melanoma [224] which reinforces a
rational combination of targeted therapy and immunotherapy. The results are not yet ma‐
ture and studies are ongoing, but there is preclinical and retrospective data that support this
model of treatment [224-227]. The following combination strategies have shown some recent
benefit and promise.
9.1. Anti-CTLA4 and IFNa
A phase II study [227] combining tremelimumab and high dose IFN in patients with ad‐
vanced melanoma showed an ORR of 24% with 4 patients obtaining a CR. Toxicity was ac‐
ceptable and the median OS was 21 months. The University of Pittsburgh group is now
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contemplating a neoadjuvant and adjuvant therapy that employs an anti-CTLA4 and IFN-α
combination strategy.
9.2. Anti-CTLA4 and GM-CSF
A phase II study through ECOG combining ipilimumab and GM-CSF is currently ongoing.
Previous studies [228] with periodic infusions of anti-CTLA-4 antibodies after vaccination
with irradiated, autologous tumor cells engineered to secrete GM-CSF have yielded favora‐
ble results with acceptable toxicity.
9.3. IL-2 and gp-100
A phase III trial evaluated the combination of IL-2 and the gp100 peptide vaccine in ad‐
vanced melanoma. This combination therapy increased the response rate (16% vs. 6%) with
more CRs in the combination arm and a trend toward increased OS [177]. Interestingly, the
single arm responses were lower than expected. A similarly designed study employing ipili‐
mumab did not show significant benefit in the combination arm [95].
10. Conclusion
Immunotherapy holds the promise of “the cure” for cancer. Glimpses of this outcome have
been seen throughout the past century but may be best exemplified in melanoma therapy.
Although attempts in the past have not had satisfactory results, the knowledge gained along
with the ability to develop biologically active drugs is bearing fruit in the current generation
of clinical trials. The few positive results have kept the interest for cancer immunotherapy
alive which has also helped us to achieve a better understanding of the immune system in
relationship to cancer treatment. The improvement in outcome seen with gp100 plus IL-2 is
impressive, and the power of the anti-cancer and autoimmune toxicities seen with ipilimu‐
mab is dramatic. The excitement stems not only from the clinical results that were obtained
but also by our ability to successfully manipulate the complex immune system in a different
way than before. Undoubtedly, there are a lot of unanswered questions including why are
there still a large number of patients who do not achieve responses with immunotherapy
and eventually die from advanced disease? However, unlike immunotherapy applied to
other advanced setting solid tumors, immunotherapy in advanced melanoma has resulted
in some durable responses and possibly cures.
The future of immunotherapy in melanoma and other tumor types would ideally involve re‐
search in a broad range of directions. An optimization of the IL-2 based treatments is needed
to improve the number of durable responses. Results from the current work at NCI aug‐
menting IL-2 treatment with lymphodepletion are quite encouraging. Identification of se‐
rum or tissue biomarkers is also urgently needed. Biomarker research is often complex, but
this work should reveal a better understanding of the tumor itself as well as the host. The
checkpoint inhibitors such as ipilimumab and tremelimumab have opened the door for re‐
search into other immunologic checkpoints such as PD-1 and co-stimulatory signals. The
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need for a reliable melanoma biomarker is again paramount, and the significance of PD-L1
expression that is currently under investigation is anticipated with interest. Studying mech‐
anisms of resistance in all cancer immunotherapeutics is equally important.
The combination of different immunotherapeutics with each other, with molecularly target‐
ed agents or with conventional treatments such as chemotherapy or radiation therapy, may
not be the simple process that combination strategies with vaccines were in the past, but this
approach is quite attractive and rational and will help us further understand the role of the
immune system in this disease. In a similar fashion, sequential therapy, using different
agents at different times might improve clinical response and survival. Appropriate first line
selection is also quite challenging since there are currently three approved agents in BRAF
V600E mutated patients (high does IL-2, ipilimumab and vemurafenib) and two for BRAF
wild type patients (high dose IL-2 and ipilimumab). A randomized clinical trial of ipilimu‐
mab followed by vemurafenib versus vemurafenib followed by ipilimumab is planned
through the NCI Cooperative Group mechanisms [218]. Future clinical trials will hopefully
provide some answers to these questions. In the design of clinical trials, the importance of
refining the RECIST criteria for immunotherapy agents cannot be overemphasized. Overall,
this is an exciting time for cancer immunologists and clinicians who treat patients with mel‐
anoma. The future for innovative trials of new agents and combinations is brighter than ever
before.
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